Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again

After clashing with oncology rivals over checkpoint inhibitor patents multiple times in the past, Bristol Myers Squibb is going after rival AstraZeneca once more.

In a new lawsuit in Delaware federal court, BMS claims AZ infringed a patent covering its blockbuster checkpoint inhibitor Opdivo.